Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Escitalopram Effective Among Patients With HIV, Generalised Anxiety Disorder: Presented at APA By Ed Susman NEW ORLEANS -- May 25, 2010 -- Patients who have generalised anxiety disorder and HIV can get relief from their psychiatric complaints without any negative impact on HIV treatment, researchers said here at the 2010 Annual Meeting of the American Psychiatric Association (APA). The researchers observed significant declines in the Hamilton Anxiety Rating Scale, indicating improvement in that aspect of the disorder, and a significant decrease in the mean Trail Making Text, an indicator that treatment with escitalopram did not have a negative impact on neurocognition. "We also did not see a negative change in the number of CD4-positive cell count or the patients' HIV viral load," said Manmohandeep Sohi, MD, Duke University, Durham, North Carolina, who will begin a residency in psychiatry in July at Louisiana State University at Shreveport. "This preliminary evidence indicates that escitalopram may have a role in treatment of generalised anxiety disorder in patients with HIV," Dr. Sohi said during his poster presentation on May 24. "The disease effect profile of escitalopram was quite similar to that observed in the general population." In the 6-week, open-label study, Dr. Sohi and colleagues recruited 20 patients who were clinically stable on a regimen of highly active antiretroviral therapy. Their mean age was 44.6 years and 13 were women. The patients were started on escitalopram 10 mg/day and were titrated to 20 mg a day if tolerated. The mean tolerated dose of escitalopram was 14.9 mg a day. The study participants recorded a mean Hamilton Anxiety Rating Scale score at baseline of 21.23, indicating moderate anxiety. There was a significant reduction in mean scores from baseline to end of treatment with a mean change of 17.62 (P < .01). Of the patients, 85% were responders according to the Clinicians Global Index. The most common side effects were nausea (3 patients), dizziness (3 patients), diarrhoea (3 patients), and dry mouth (2 patients). "We did not observe any clinically significant interactions of escitalopram with existing antiviral therapy," Dr. Sohi said. He also said there was no significant weight gain or loss among the patients when baseline weight was compared to the end of the study. Funding for this study was provided by Forest Research Institute. [Presentation title: An Open-Label, Rater Blinded 6-Week Pilot Trial of Escitalopram for Generalized Anxiety Disorder Among Patients With HIV. Abstract NR1-20] E-mail this page to a friend or colleague! To print, use this version